Impact of CVVHD With Adsorption Capacity Membranes in Septic Acute Kidney Injury

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

October 31, 2017

Conditions
SepsisSeptic ShockAcute Kidney Injury
Interventions
OTHER

CVVHD

CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

OTHER

CVVH

CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

Trial Locations (2)

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Hospital de Sant Pau

OTHER

lead

Hospital Universitari de Bellvitge

OTHER

NCT01790620 - Impact of CVVHD With Adsorption Capacity Membranes in Septic Acute Kidney Injury | Biotech Hunter | Biotech Hunter